CD19 and acute lymphoblastic leukemia: A novel second-generation CD19 CAR-T cell therapy with a fast binding off rate for CD19 (AUTO1), designed with the aim to reduce toxicity and to improve persistence, was tested in a phase I study of 20 adult patients with R/R ALL.